Abstract:Objective: With the proposal of penumbra theory and development of intra-arterial thrombolysis (such as urokinase), the outcome of ischemic cerebrovascular disease is greatly improved. However, the incidence of hemorrhagic transformation (HT) increased concomitantly, and some studies showed a close relationship between blood pressure and HT. The mechanisms of blood pressure and urokinase effect on the incidence of HT are not clear. In this study, we investigated the effects of the different levels of blood pressure and urokinase on the ischemic lesions, the incidence of HT and the expression of matrix metalloproteinase 9 (MMP-9) in the rat ischemia-reperfusion models. Methods: Temporary focal ischemia was induced in male Sprague-Dawley rats using the intraluminal vascular occlusion method. The animals were assigned into four groups (n=11 in each group): low blood pressure group (LP), normal blood pressure group (NP), high blood pressure group (HP) and urokinase/high blood pressure group (UKHP). Adnephrin was applied to enhance the mean arterial blood pressure (MABP) at the beginning of reperfusion. MABP was maintained 20 mmHg higher than the baseline for 1 hour. Sodium nitroprusside was used to decrease MABP by 20 mmHg lower than the baseline for 1 hour. Both urokinase and adnephrin were used concomitantly in the UKHP group. Neurological deficit scores were evaluated at 2 hours (R2h) and 24 hours (R24h) after reperfusion. All rats were decapitated, their brains were sliced into 15-mu m-thick slices, and the infarct volume and the visible HT were analysed. Three rats in each group were taken for immunohistochemistry and pathological analysis. Results: There was no significant difference in MABP among the groups at the baseline time points (p>0.05), but blood pressure are definitely increased and decreased in the HP, UKHP, and LP groups. Neurological deficit scores showed no significant difference at R2h among the groups (p=0.443). However, neurological deficit scores showed significant differences at R24h among the groups, the neurological deficits scores of rats in the LP group are significantly higher than that in the other groups. Compared with that of 2 hours after reperfusion, neurological deficit scores deteriorated in the LP group (p=0.047) but was improved in the NP, HP and UKHP groups (p=0.076, 0.002, 0.017, respectively) at 24 hours after reperfusion. The infarct volume in the HP group was apparently smaller than that in the LP group (p=0.006). There was indeed a tendency that HT occurred more frequently in the UKHP group (42.8%) than in the HP (25%) and LP (28.5%) groups. MMP-9 expression showed significant increase around the ischemic lesion areas of the UKHP group and significant decrease in the cortical areas of the LP and HP groups but no significant difference in the basal ganglia of rats of all groups. Conclusion: Mild elevation of blood pressure during reperfusion is supposed to improve neurological outcomes in rats following ischemia/reperfusion. The incidence of HT tended to increase with the elevation of blood pressure and the administration of urokinase. Immunohistochemitry analysis indicated that incidence of HT may correlate with excessive expression of MMP-9. [Neurol Res 2009; 31: 204-208]

Urinary trypsin inhibitor suppresses excessive superoxide anion radical generation in blood, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats

Effects of Ulinastatin on Renal Ischemia-Reperfusion Injury in Rats

Protection Effects of Ulinastatin Against Lung Warm Ischemia-Reperfusion Injury in Rats

Effects of Ulinastatin on Global Ischemia Via Brain Pro-Inflammation Signal.

Neuroprotection of Ulinastatin on Transient Cerebral Ischemia Via Antioxidative Mechanisms.

Effects of Ulinastatin, A Urinary Trypsin Inhibitor, on Synaptic Plasticity and Spatial Memory in A Rat Model of Cerebral Ischemia/Reperfusion Injury

Ulinastatin alleviates early brain injury after intracerebral hemorrhage by inhibiting oxidative stress and neuroinflammation via ROS/MAPK/Nrf2 signaling pathway

Urinary Trypsin Inhibitor Attenuates Hepatic Ischemia-Reperfusion Injury by Reducing Nuclear Factor-Kappa B Activation

Protective Effects Of Urinary Trypsin Inhibitor On Vascular Permeability Following Subarachnoid Hemorrhage In A Rat Model

Ulinastatin alleviates early brain injury after traumatic brain injury by inhibiting oxidative stress and apoptosis

Ulinastatin attenuates renal ischemia-reperfusion injury by inhibiting NLRP3 inflammasome-triggered pyroptosis

Ulinastatin Alleviates Neurological Deficiencies Evoked by Transient Cerebral Ischemia Via Improving Autophagy, Nrf-2-ARE and Apoptosis Signals in Hippocampus

The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.

Ulinastatin Attenuates Lps-Induced Human Endothelial Cells Oxidative Damage Through Suppressing Jnk/C-Jun Signaling Pathway

Effects of ulinastatin on delayed cerebral vasospasm following subarachnoid hemorrahage in rats and its neuroprotection

Ulinastatin Attenuates the Inflammatory Reaction Induced by Hepatic Ischemia Reperfusion in Rats

Does Urinary Trypsin Inhibitor Have A Role In Acute Lung Injury Induced By Pulmonary Contusion: A Basic Research In A Model Of Rats

Ulinastatin attenuates LPS-induced inflammation in mouse macrophage RAW264.7 cells by inhibiting the JNK/NF-κB signaling pathway and activating the PI3K/Akt/Nrf2 pathway

Effect of Ulinastatin on the Permeability of the Blood-Brain Barrier on Rats with Global Cerebral Ischemia/reperfusion Injury As Assessed by MRI.

Ulinastatin prevents acute lung injury led by liver transplantation

The Preventive Effect of Urinary Trypsin Inhibitor on Postoperative Cognitive Dysfunction, on the Aspect of Behavior, Evaluated by Y-Maze Test, via Modulation of Microglial Activity